- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04524689
Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05) (CARMEN-LC05)
February 6, 2024 updated by: Sanofi
Open-label, Phase 2 Study of Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
Primary Objective:
- Safety run-in part: to assess the tolerability and to determine the recommended doses of tusamitamab ravtansine in combination with pembrolizumab and tusamitamab ravtansine in combination with pembrolizumab and platinum-based chemotherapy with or without pemetrexed to be tested in the expansion part of the study in the NSQ NSCLC population
- Expansion part (including participants treated at the recommended dose for expansion [RDE] from the Safety Run-in part): to assess the antitumor activity of several dose levels (DLs; if applicable) of tusamitamab ravtansine in combination with pembrolizumab and of several DLs of tusamitamab ravtansine in combination with pembrolizumab, platinum-based chemotherapy, and pemetrexed in the NSQ NSCLC population
Secondary Objectives:
- To assess the safety and tolerability of several DLs (if applicable) of tusamitamab ravtansine in combination with pembrolizumab and of 1 DL of tusamitamab ravtansine in combination with pembrolizumab and platinum-based chemotherapy, and of several DLs of tusamitamab ravtansine in combination with pembrolizumab, and platinum-based chemotherapy with pemetrexed in the NSQ NSCLC population
- To assess the antitumor activity of several DLs (if applicable) of tusamitamab ravtansine in combination with pembrolizumab and of 1 DL of tusamitamab ravtansine in combination with pembrolizumab and platinum-based chemotherapy, and of several DLs of tusamitamab ravtansine in combination with pembrolizumab, platinum-based chemotherapy, and pemetrexed in the NSQ NSCLC population
- To assess the durability of the response to treatment with several DLs (if applicable) of tusamitamab ravtansine in combination with pembrolizumab and of 1 DL of tusamitamab ravtansine in combination with pembrolizumab and platinum-based chemotherapy, and of several DLs of tusamitamab ravtansine in combination with pembrolizumab and platinum-based chemotherapy, and pemetrexed in the NSQ NSCLC population
- To assess the antitumor activity of tusamitamab ravtansine in combination with pembrolizumab and platinum-based chemotherapy in the NSQ NSCLC population
- To assess the pharmacokinetics (PK) of tusamitamab ravtansine, pembrolizumab, pemetrexed, cisplatin, and carboplatin, each when given in combination as a doublet (tusamitamab ravtansine + pembrolizumab) or a triplet (tusamitamab ravtansine + pembrolizumab + platinum-based chemotherapy) or a quadruplet (tusamitamab ravtansine + pembrolizumab + platinum-based chemotherapy + pemetrexed)
- To assess the immunogenicity of tusamitamab ravtansine in combination with pembrolizumab and tusamitamab ravtansine in combination with pembrolizumab and platinum based chemotherapy with or without pemetrexed
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Detailed Description
The expected duration of study intervention for participants may vary, based on disease progression date; median expected duration of study per participant is estimated at 10 months (up to 1 month for screening, a median of 6 months for treatment, a median of 1 month for EOT, and follow-up visit 90 days after the last IMP administration).
Study Type
Interventional
Enrollment (Actual)
57
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Trial Transparency email recommended (Toll free number for US & Canada)
- Phone Number: option 6 800-633-1610
- Email: Contact-US@sanofi.com
Study Locations
-
-
Rio Grande Do Norte
-
Natal, Rio Grande Do Norte, Brazil, 59062-000
- Centro Avancado de Oncologia CECAN - Liga Contra o Cancer Site Number : 0760004
-
-
-
-
-
Santiago, Chile, 7500713
- Orlandi Oncologia General Salvo 159, Providencia_Investigational Site Number :1520002
-
Santiago, Chile, 8241470
- ICEGCLINIC Avenida Serafín Zamora 190 Torre B, piso 4. La Florida_Investigational Site Number :1520006
-
-
La Araucanía
-
Temuco, La Araucanía, Chile, 4780000
- Centro de Investigacion y Desarrollo Oncologico (CIDO) Hochstetter 599 of. 602-603-1001, Temuco_Investigational Site Number :1520005
-
-
Valparaíso
-
Viña del Mar, Valparaíso, Chile, 2520598
- ONCOCENTRO APYS Av. La Marina 1702, 2do piso, Viña del Mar_Investigational Site Number :1520003
-
-
-
-
-
Olomouc, Czechia, 77900
- Fakultní nemocnice Olomouc Onkologická klinika I.P. Pavlova 6_Site Number :2030001
-
Ostrava - Vitkovice, Czechia, 70384
- Nemocnice AGEL Ostrava - Vitkovice Plicní oddělení Zalužanského 2214/35_Site Number :2030002
-
-
-
-
-
Avignon, France, 84918
- Institut Sainte-Catherine 250 Chemin de Baigne-Pieds_Investigational Site Number :2500005
-
Brest, France, 29200
- CHRU BREST 5 Avenue Foch_Investigational Site Number :2500003
-
Pessac, France, 33600
- Centre François Magendie Hôpital du Haut Lévèque Av.de Magellan_Investigational Site Number :2500001
-
Poitiers Cedex, France, 86021
- Pôle régional de Cancérologie 2 rue de la Milèterie BP 577_Investigational Site Number :2500004
-
-
-
-
-
Budapest, Hungary, 1083
- Investigational Site Number :3480003
-
Budapest, Hungary, 1122
- Országos Onkológiai Intézet Ráth György u. 7_Investigational Site Number :3480002
-
Farkasgyepü, Hungary, 8582
- Veszprém Megyei Tüdőgyógyintézet 049/2 Hrsz_Investigational Site Number :3480004
-
-
-
-
-
Jerusalem, Israel, 91031
- Investigational Site Number : 3760004
-
Ramat Gan, Israel, 5266202
- Investigational Site Number : 3760001
-
Tel Aviv, Israel, 64239
- Investigational Site Number : 3760002
-
-
-
-
-
Las Palmas, Spain, 35016
- Investigational Site Number : 7240002
-
Madrid, Spain, 28041
- Investigational Site Number : 7240001
-
Madrid, Spain, 28040
- Investigational Site Number : 7240004
-
-
A Coruña [La Coruña]
-
La Coruña, A Coruña [La Coruña], Spain, 15006
- Investigational Site Number : 7240005
-
-
Asturias
-
Oviedo, Asturias, Spain, 33011
- Investigational Site Number : 7240007
-
-
Catalunya [Cataluña]
-
Badalona, Catalunya [Cataluña], Spain, 08916
- Investigational Site Number : 7240006
-
-
Valenciana, Comunidad
-
Valencia / Valencia, Valenciana, Comunidad, Spain, 46010
- Investigational Site Number : 7240003
-
-
-
-
California
-
Encinitas, California, United States, 92024
- cCare/California Cancer Associates Site Number : 8400005
-
-
Kansas
-
Westwood, Kansas, United States, 66205
- KU Medical Center_Investigational Site Number :8400002
-
-
Texas
-
The Woodlands, Texas, United States, 77380
- Renovatio Clinical_Investigational Site Number :8400004
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Virginia Cancer Specialists_Investigational Site Number :8400001
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion criteria :
- Histologically- or cytologically-confirmed diagnosis of advanced or metastatic NSQ NSCLC with no EGFR sensitizing mutation or BRAF mutation or ALK/ROS alterations.
- No prior systemic chemotherapy for the treatment of the participant's advanced or metastatic disease (treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as completed at least 6 months prior to diagnosis of advanced or metastatic disease).
- Expression of CEACAM5 as demonstrated prospectively by a centrally assessed Immunohistochemistry (IHC) assay of ≥2+ in intensity involving at least 1% of the tumor cell population in archival tumor sample (or if not available fresh biopsy sample).
- Measurable disease based on RECIST 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
- Life expectancy of at least 3 months
Exclusion criteria:
- Medical condition requiring concomitant administration of a medication with a strong CYP3A inhibitor.
- Uncontrolled brain metastases and history of leptomeningeal disease.
- Significant concomitant illness, including any severe medical condition that, in the opinion of the investigator or Sponsor, would impair the patient's participation in the study or interpretation of the results.
- History within the last 3 years of an invasive malignancy other than the one treated in this study, with the exception of resected/ablated basal or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix, or other local tumors considered cured by local treatment.
- History of known acquired immunodeficiency syndrome (AIDS) related illnesses or known HIV disease requiring antiretroviral treatment, or active hepatitis A, B, or C infection.
- History of active autoimmune disease that has required systemic treatment in the past 2 years.
- History of allogeneic tissue/solid organ transplantation.
- Active infection requiring IV systemic therapy within 2 weeks prior to randomization or active tuberculosis.
- Interstitial lung disease or history of pneumonitis that has required oral or IV steroids
- Non-resolution of any prior treatment-related toxicity to < Grade 2 according to NCI CTCAE V5.0, with the exception of alopecia, vitiligo, or active thyroiditis controlled with hormone replacement therapy.
- Unresolved corneal disorder or any previous corneal disorder considered by an ophthalmologist to predict higher risk of drug-induced keratopathy. The use of contact lenses is not permitted.
- Symptomatic herpes zoster within 3 months prior to screening.
- Significant allergies to humanized monoclonal antibodies.
- Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A [IgA] dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis).
- Concurrent treatment with any other anticancer therapy.
- Have received prior chemotherapy treatment for advanced/metastatic NSCLC.
- The patient is a candidate for a curative treatment with either surgical resection and/or chemoradiation
- Washout period before the first administration of study intervention of less than 3 weeks or less than 5 times the half-life, whichever is shorter, for any investigational treatment).
- Any prior therapy targeting CEACAM5.
- Any prior treatment with any other anti-PD-1, or PD-L1 or programmed death ligand 2 (PD-L2), anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4.
- Any prior maytansinoid treatment (DM1 or DM4 ADC).
- Is receiving systemic steroid therapy ≤3 days prior to the first dose of study therapy or receiving any other form of immunosuppressive medication. Daily steroid replacement therapy or any corticosteroid premedication if applicable are allowed.
- Any radiation therapy to lung >30 Gy within 6 months of first study intervention administration.
- Has received or will receive a live vaccine within 30 days prior to the first study intervention administration.
- Any major surgery within the preceding 3 weeks of the first study intervention administration.
Prior/concurrent clinical study experience
- Current participation in any other clinical study involving an investigational study treatment or any other type of medical research.
- Poor organ function
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tusamitamab ravtasine + Pembrolizumab
Pembrolizumab dose will be administered intravenously prior to intravenous administration of tusamitamab ravtansine dose every 3 weeks.
|
Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
Other Names:
Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
Other Names:
|
Experimental: Tusamitamab ravtansine + Pembrolizumab + carboplatin or cisplatin
Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks.
Carboplatin will be infused over 15 to 60 minutes immediately after tusamitamab ravtansine infusion on Day 1 and Q3W for the first 4 cycles.
Cisplatin will be infused approximately 30 minutes after tusamitamab ravtansine infusion on Day 1 and Q3W for the first 4 cycles.
|
Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
Other Names:
Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
Other Names:
Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
Pharmaceutical form: Lyophilized powder for reconstitution in solution Route of administration: Intravenous
|
Experimental: Tusamitamab ravtansine + Pembrolizumab + carboplatin or cisplatin + pemetrexed
Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks.
Pemetrexed will be infused over 10 minutes after tusamitamab ravtansine infusion on Day 1 and then Q3W.
Carboplatin will be infused over 15 to 60 minutes immediately after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles.
Cisplatin will be infused approximately 30 minutes after pemetrexed infusion after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles.
|
Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
Other Names:
Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
Other Names:
Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
Pharmaceutical form: Lyophilized powder for reconstitution in solution Route of administration: Intravenous
Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Drug-related dose-limiting toxicity (DLTs)
Time Frame: Baseline up to 10 months after last participant treated
|
Study drug-related dose-limiting toxicity (DLTs) at Cycle 1 (C1D1 to C1D21), including but not limited to corneal toxicity.
Each cycle is 21 days.
|
Baseline up to 10 months after last participant treated
|
Incidence of study drug-related dose-limiting toxicity (DLTs) at Cycle 1 (C1D1 to C1D21)
Time Frame: Baseline up to 21 days
|
DLTs observed during the DLT observation period (Cycle 1) will be summarized on the DLT-evaluable population, by part, DL, and overall (if applicable)
|
Baseline up to 21 days
|
Expansion part (including participants treated at the recommended dose for expansion [RDE] from the Safety Run-in part): Objective response rate (ORR)
Time Frame: Baseline up to approximately 4.5 months after last participant first treated
|
ORR defined as proportion of participants who have a confirmed complete response (CR) or partial response (PR) as best overall response per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
|
Baseline up to approximately 4.5 months after last participant first treated
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and laboratory abnormalities
Time Frame: Baseline up to 10 months after last participant treated
|
TEAEs, SAEs and laboratory abnormalities according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) V5 -
|
Baseline up to 10 months after last participant treated
|
Objective response rate (ORR) of tusamitamab ravtansine + pembrolizumab + platinum based chemotherapy, with or without pemetrexed
Time Frame: Baseline up to 10 months after last participant treated
|
ORR is defined as proportion of participants who have a confirmed complete response (CR) or partial response (PR) as per response evaluation criteria in solid tumors (RECIST v1.1)
|
Baseline up to 10 months after last participant treated
|
Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and laboratory abnormalities according to Common Terminology Criteria for Adverse Events (CTCAE) V5.0
Time Frame: Baseline up to 30 days after last IMP administration
|
An overall summary of TEAEs will be provided.
The number and percentage of participants experiencing any of the following will be provided: TEAEs, Grade ≥3 TEAEs, Grade 5 TEAEs , Serious TEAEs, TEAEs leading to permanent treatment discontinuation, Treatment-related TEAEs, Treatment-related TEAEs Grade ≥3, Serious treatment-related TEAEs, Adverse events of special interest (AESI), deaths and clinical laboratory values according to CTCAE V5.0
|
Baseline up to 30 days after last IMP administration
|
Progression-free survival (PFS)
Time Frame: Baseline up to 10.5 months after first IMP administration of the last participant
|
PFS is defined as the time from the first investigational medicinal product (IMP) administration to the date of the first documented disease progression or death due to any cause, whichever comes first (not for Part B).
|
Baseline up to 10.5 months after first IMP administration of the last participant
|
Disease control rate (DCR)
Time Frame: Baseline up to 4.5 months after first IMP administration of the last participant
|
DCR, defined as the percentage of participants who have achieved confirmed CR, confirmed PR, or stable disease (SD) as best overall response (BOR) per RECIST v1.1 Baseline up to 4.5 months after first IMP administration of the last participant
|
Baseline up to 4.5 months after first IMP administration of the last participant
|
Duration of response (DOR)
Time Frame: Baseline up to 10.5 months after first IMP administration of the last participant
|
DOR, defined as the time from first documented evidence of CR or PR until progressive disease (PD) determined per RECIST v1.1 or death from any cause, whichever occurs first
|
Baseline up to 10.5 months after first IMP administration of the last participant
|
ORR
Time Frame: Baseline up to 4.5 months after first IMP administration of the last participant
|
ORR, defined as proportion of participants who have a confirmed CR or PR as per BOR per RECIST v1.1
|
Baseline up to 4.5 months after first IMP administration of the last participant
|
Pharmacokinetic concentrations
Time Frame: PK concentrations assessed at multiple timepoints up to C13 for tusamitamab ravtansine, up to cycle 8 for pembrolizumab, up to cycle 1 for cisplatin, carboplatin and pemetrexed
|
PK Ctrough at C2D1 for tusamitmab ravtansine (SAR408701, DM4, Me-DM4) and pembrolizumab PK End of infusion at C1D1 for cisplatin and carboplatin PK 30 min at C1D1 for pemetrexed
|
PK concentrations assessed at multiple timepoints up to C13 for tusamitamab ravtansine, up to cycle 8 for pembrolizumab, up to cycle 1 for cisplatin, carboplatin and pemetrexed
|
Incidence of anti-therapeutic antibodies (ATAs) against tusamitamab ravtansine
Time Frame: Baseline up to 10.5 months after first IMP administration of the last participant
|
Incidence of anti-therapeutic antibodies (ATAs) against tusamitamab ravtansine
|
Baseline up to 10.5 months after first IMP administration of the last participant
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Clinical Sciences & Operations, Sanofi
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 26, 2020
Primary Completion (Estimated)
April 10, 2024
Study Completion (Estimated)
December 30, 2024
Study Registration Dates
First Submitted
August 20, 2020
First Submitted That Met QC Criteria
August 20, 2020
First Posted (Actual)
August 24, 2020
Study Record Updates
Last Update Posted (Actual)
February 8, 2024
Last Update Submitted That Met QC Criteria
February 6, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Folic Acid Antagonists
- Carboplatin
- Pembrolizumab
- Maytansine
- Pemetrexed
Other Study ID Numbers
- ACT16146
- U1111-1233-9798 (Registry Identifier: ICTRP)
- 2023-509115-84 (Registry Identifier: CTIS)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants.
Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of, United Kingdom
-
AIO-Studien-gGmbHAstraZenecaTerminatedNSCLC | Non-squamous Non-small Cell Lung Cancer Stage II | Non-squamous Non-small Cell Lung Cancer Stage IIIA | Non-squamous Non-small Cell Lung Cancer Stage IIIB | Activating EGFR MutationGermany
-
AmgenParexelWithdrawnMetastatic Non-small Cell Lung Cancer (NSCLC) | Non-squamous NSCLC
-
Rain Oncology IncTerminatedNSCLC | Non-small Cell Lung Cancer | Non-squamous NSCLCUnited States, Australia
-
Radiotherapy Oncology Centre "Santa Maria" HospitalPaola Anselmo,MD; Michelina Casale,PhD; Fabio Trippa,MDRecruitingNSCLC | Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Oligometastatic Disease | Non-Small Cell Squamous Lung Cancer | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | Non-Small Cell Adenocarcinoma and other conditionsItaly
-
H. Lee Moffitt Cancer Center and Research InstituteNestle Health ScienceWithdrawnNSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | NSCLC Stage IIIB | Non-small Cell Lung Cancer Stage IIIB | NSCLC, Stage IIIA | Non-small Cell Lung Cancer Stage ⅢAUnited States
-
ElephasBeaufort CRORecruitingNSCLC | Non Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Metastatic NSCLC - Non-Small Cell Lung CancerUnited States
-
Peking University First HospitalMerck Sharp & Dohme LLCNot yet recruitingAdvanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung CancerChina
-
Western Regional Medical CenterTerminatedNon-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer | Squamous Cell Non-Metastatic Non-Small Cell Lung CancerUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingNSCLC | Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Non-small Cell CarcinomaUnited States
Clinical Trials on SAR408701 (Tusamitamab ravtansine)
-
Erasmus Medical CenterSanofiWithdrawnMetastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerNetherlands
-
SanofiActive, not recruitingNon-squamous Non-small Cell Lung CancerBelgium, Italy, Spain, Japan, United States, France, Turkey
-
SanofiTerminatedNeoplasmFrance, United States, Belgium, Spain, Turkey
-
SanofiActive, not recruitingBreast Cancer Metastatic | Pancreatic Carcinoma MetastaticSpain, Korea, Republic of, Turkey, Chile, Netherlands, Russian Federation, Taiwan, United States, Argentina, Hungary
-
SanofiActive, not recruitingAdenocarcinoma Gastric | Gastrooesophageal CancerJapan, Belgium, Korea, Republic of, Spain, Russian Federation, Turkey
-
Innovent Biologics (Suzhou) Co. Ltd.Not yet recruitingNon-squamous Non-small-cell Lung CancerChina
-
SanofiActive, not recruitingNeoplasm MalignantUnited States, Canada, France, Korea, Republic of, Spain
-
SanofiCompletedNeoplasm MalignantJapan
-
Cairo UniversityRecruiting
-
SanofiActive, not recruitingNon-small Cell Lung Cancer MetastaticGreece, Italy, Hungary, Belgium, Korea, Republic of, Turkey, Argentina, China, Spain, Chile, Poland, Australia, United States, Russian Federation, Brazil, Bulgaria, Canada, France, Germany, India, Israel, Japan, Lithuania, Mexico, Nethe... and more